Jarari Abdalla M, Peela Jagannadha R, Zakoko Ahmed, Hawda Salima, Abd El Rasoul Hala, Peela Anirudh Srinivas T, Addagarla Sreeja, Madompoyil Basheer
Biochemistry, Benghazi Medical Center, Benghazi, LBY.
Biochemistry and Genetics, Bioprist Institute of Health and Medical Sciences, Montego Bay, JAM.
Cureus. 2025 Apr 15;17(4):e82293. doi: 10.7759/cureus.82293. eCollection 2025 Apr.
Psychiatric disorders, including schizophrenia, bipolar disorder, and drug-induced psychosis, are associated with significant biochemical and hematological alterations. Antipsychotic medications, particularly second-generation antipsychotics, have been implicated in metabolic disturbances, hormonal imbalances, and hematological changes.
This study aimed to evaluate the impact of psychiatric disorders and antipsychotic medications on metabolic and hematological parameters, identifying potential risks associated with long-term treatment.
A prospective hospital-based study was conducted on 80 psychiatric patients and 15 healthy controls. Biochemical markers, such as fasting blood sugar (FBS), glycated hemoglobin (HbA1c), lipid profile, C-reactive protein (CRP), thyroid-stimulating hormone (TSH), and prolactin, were assessed. Hematological parameters, including hemoglobin (Hb), white blood cell (WBC) count, platelet count, and serum albumin, were analyzed. Statistical comparisons were conducted using IBM SPSS Statistics for Windows, Version 23.0 (Released 2015; IBM Corp., Armonk, NY, United States), with significance set at p < 0.05.
Psychiatric patients showed higher levels of HbA1c, CRP, low-density lipoprotein (LDL), and prolactin compared to controls. Second-generation antipsychotics (SGAs) were more strongly associated with metabolic dysregulation than first-generation antipsychotics (FGAs). Hematological alterations included lower hemoglobin and higher platelet count in psychiatric patients.
Psychiatric disorders and antipsychotic therapy are associated with significant metabolic and hematological changes, requiring regular monitoring and preventive strategies.
精神疾病，包括精神分裂症、双相情感障碍和药物性精神病，与显著的生化和血液学改变有关。抗精神病药物，尤其是第二代抗精神病药物，与代谢紊乱、激素失衡和血液学变化有关。
本研究旨在评估精神疾病和抗精神病药物对代谢和血液学参数的影响，确定与长期治疗相关的潜在风险。
对80名精神科患者和15名健康对照者进行了一项基于医院的前瞻性研究。评估了生化指标，如空腹血糖（FBS）、糖化血红蛋白（HbA1c）、血脂谱、C反应蛋白（CRP）、促甲状腺激素（TSH）和催乳素。分析了血液学参数，包括血红蛋白（Hb）、白细胞（WBC）计数、血小板计数和血清白蛋白。使用IBM SPSS Statistics for Windows 23.0版（2015年发布；IBM公司，美国纽约州阿蒙克）进行统计比较，显著性设定为p < 0.05。
与对照组相比，精神科患者的HbA1c、CRP、低密度脂蛋白（LDL）和催乳素水平更高。第二代抗精神病药物（SGA）比第一代抗精神病药物（FGA）与代谢失调的关联更强。血液学改变包括精神科患者血红蛋白降低和血小板计数升高。
精神疾病和抗精神病治疗与显著的代谢和血液学变化有关，需要定期监测和预防策略。
